Search Clinical Trials

Clinical Trials Condition

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

26 results for "Neuroscience"

Utilization of Target Ranges to Treat Patients With Parkinson’s Disease by Objective Measurement Using the Personal KinetiGraph (PKG) Compared to Standard of Care Assessment (TARGET-PD)

The purpose of this project is to evaluate whether patients with Parkinson’s disease who are managed with standard of care and the aid of target ranges reported on the PKG have improved Parkinson’s disease symptoms and outcomes compared to patients treated only with standard of care. 

Primary Investigator: Ryan Brennan, DO

Sub Category
Parkinson's and Movement Disorders

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants w/ Parkinson’s Disease

The primary objective of this two-cohort study is to assess the safety and tolerability of the daily oral administration of Nilotinib or placebo in participants with moderate to advanced PD (Cohort 1) and in participants with early/de novo PD (Cohort 2). Participants in Cohort 2 will be treated with the selected dose determined in Cohort 1 or matching placebo. Cohort 1 will be treated with Nilotinib 150mg, 300mg, or matching placebo.   

Primary Investigator: Karen Blindauer, MD

Sub Category
Parkinson's and Movement Disorders

SPARK-PD - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BIIB054 in Subjects With Parkinson’s Disease

The primary objective of this study is to evaluate the dose-related safety of BIIB054. There is a placebo-controlled treatment period (48 weeks) followed by a dose-blinded active treatment (48 weeks).

Primary Investigator: Karen Blindauer, MD

Sub Category
Parkinson's and Movement Disorders

IPSEN Abolish: Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)

Observational study to assess the longitudinal attainment of person centered and function related goals after one or more abobotulinum toxin A (aboBoNT-A) injections in the lower limb using the cumulated Goal Attainment Scaling -Leg (GASleg) T score in a real life clinical setting.

Primary Investigator: Nicholas Ketchum, MD

Status: Currently Enrolling

Sub Category
Stroke and Neurovascular

SleepSmart: The Sleep for Stroke Management and Recovery Trial

Designed to evaluate ischemic stroke patients or patients with transient ischemic attack (TIA) for obstructive sleep apnea. Patients who qualify, will help assess whether continuous positive airway pressure (CPAP) for obstructive sleep apnea, after stroke, helps with recovery or helps prevent another stroke.

Status: Currently enrolling

Sub Category
Stroke and Neurovascular

Stroke Recruitment Database

The database is designed specifically to serve as a screening and recruitment tool for stroke researchers in the greater Milwaukee Area, matching stroke survivors willing to contribute to science as research participants with study coordinators seeking to populate their studies with individuals meeting their particular inclusion/exclusion criteria.

Sub Category
Stroke and Neurovascular
Share This: